DNA engineering technology, allowing one to assemble DNA fragments like Lego pieces, has revolutionized biology. In this issue, Poser, Sarov and colleagues describe the BAC TransgeneOmics pipeline-a generic, highthroughput methodology that allows for the rapid generation of large DNA constructs, which will facilitate systematic characterization of protein function in mammals 1 .
Since its advent more than three decades ago 2 , recombinant DNA technology has completely changed our way of approaching biological questions and has provided invaluable tools for in-depth exploration and understanding of living systems. All DNA engineering methodologies are conceptually the same in that they aim to build new, artificial DNA molecules by stitching together pre-existing pieces. Two main technological branches have emerged: the classical restriction and ligation-based (copy and paste) strategies, and a set of advanced in vivo methods, referred to as 'recombineering' 3 .
Classical copy-and-paste techniques are suitable for engineering relatively small and simple constructs that can comfortably accommodate entire genes from primitive genomes. These strategies, together with the use of generic DNA modules (for example, affinity tags), applied to yeast have yielded some of the most detailed and rich interactome 4-6 and localization 7 maps to date.
The classical techniques, however, are dependent on the availability of appropriate restriction sites and on the size of the fragments to be combined. This makes their implementation in higher organisms difficult, as those organisms tend to have longer genes with more complex structure and regulation and generally require larger, more sophisticated constructs that often require multiple cloning steps. And even though simpler organisms like yeast and bacteria make our wine, bread and cheese, we ultimately want to understand mice and men; recombineering now makes this possible.
The generic pipeline that Poser, Sarov and colleagues describe-called BAC TransgeneOmics-allows for simple, rapid (and hence inexpensive) high-throughput generation of large DNA constructs, permitting the systematic exploration of interactomes in higher organisms (Fig. 1) . The method uses a high-fidelity phage protein-based in vivo recombineering strategy 8,9 for modifying BACs. BACs are the vectors of choice in metazoans as they are stable and can harbor very large DNA inserts that encompass complete transcription units together with their regulatory elements. This, in turn, allows a transgene to be expressed at near-physiological levels and largely preserves its in vivo regulation. Highquality BAC libraries compatible with the TransgeneOmics pipeline are readily available for several organisms.
To validate their methodology, the authors used a modified version of the LAP tag 10 , a modular protein tag containing enhanced GFP (for protein localization and affinity purification) and S-peptide (for affinity purification), and successfully generated a large number of BAC transgenes. They placed particular emphasis on tailoring the system for liquid handling, thus making it more amenable for high-throughput studies. Indeed, using the BAC TransgeneOmics pipeline, complex constructs can be generated in less than a week. Creation of a whole-genome your favorite tag (YFT)-tagged mouse or human set is now feasible in a matter of months. As recombineering is essentially DNA context-independent, one can now conceive any construct architecture. The power of biochemistry (affinity purification) as well as genetics (dominant-negative, null or overexpression alleles) can be unleashed for large-scale protein characterization in higher eukaryotes. Moreover, as the endogenous regulation is effectively preserved, it now becomes possible to address questions with respect to specific cell types and tissues with relative ease.
Recombineering may represent a paradigm shift in our ways of manipulating DNA. And even though custom gene synthesis is now gaining momentum and becoming more accurate and affordable, recombineering will be important in functional genomics in mammalian systems over the next several years as it provides unparalleled flexibility, robustness and fidelity at a reasonable price.
Archimedes once said, "Give me a lever long enough and a fulcrum on which to place it, and I shall move the world." With the recent advances in genome sequencing and the exponential increase of available genomes, we may already have the fulcrum. We now need the lever, and Poser, Sarov and colleagues have made a big leap in that direction. Simple, yet powerful and inexpensive techniques like the BAC TransgeneOmics pipeline should be easy to implement. Therefore, in the near future, interactome maps from higher eukaryotes will become available that will rival the quality and coverage of ones that we now have for simpler model organisms. 
Metastasis: two assays explore the two roads traveled

Diane Renee Bielenberg
A spheroid assay that recapitulates angiogenesis in vivo and a ring assay to measure lymphangiogenesis in vitro expand the toolbox of techniques to investigate these processes during development and tumor progression.
Metastasisthe spread of tumor cells from the primary site to distant organsis the leading cause of death from cancer. Tumor cells disseminate through two main routes, blood vessels and lymphatic vessels (Fig. 1) . Currently, few assays can accurately depict the angiogenic or lymphangiogenic cascade. In this issue of Nature Methods, two articles describe innovative methods to model angiogenesis 1 and lymphangiogenesis 2 in vivo and in vitro.
As tumors expand beyond a small size, the need for oxygen and nutrients increases. Angiogenesisnew blood vessel formationnot only allows tumors to grow but also provides a conduit for tumor cell escape 3 . Tumor neovasculature is immature and leaky, leading to increased interstitial fluid volume and pressure, requiring lymphatic vessel drainage 4 . Lymphangiogenesis, which is the growth Diane Renee Bielenberg is in the Program in Vascular Biology, Department of Surgery, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. e-mail: diane.bielenberg@childrens.harvard.edu or expansion of lymphatic vessels, is common around the periphery of tumors and results in lymphatic vessels with massive lumens. These grossly dilated lymphatics may uptake tumor cells in the microenvironment and transport them to regional lymph nodes 4 . In fact, lymph nodes are often the first sites of metastasis.
Alajati, Laib, Weber et al. describe a new angiogenesis model in which human endothelial cells grown initially as spheroids in vitro are transplanted subcutaneously into immunocompromised mice in a Matrigel-fibrin matrix containing selected growth factors 1 . Days later, these spheroidal endothelial cell aggregates assemble into tube-like structures and within a few weeks form three-dimensional human vascular networks. Notably, some grafted vessels are functional, meaning that they contain patent lumens, are able to anastomose with existing mouse vessels and are perfused with mouse red blood cells.
The traditional Matrigel in vivo angiogenesis assay relies on the sprouting of host vessels into Matrigel spiked with growth factors. These assays are hampered by their low reproducibility and the recruitment of immune cells (macrophages) and few endothelial cells. An advantage of the spheroid assay described in this issue of Nature Methods is that endothelial cells are mixed with the matrix before implantation 1 . Spheroidal endothelial cells may have an initial survival advantage over single-cell dispersed endothelial cells.
Another perk of this assay 1 is the origin of the endothelial cells, namely human. Many anticancer therapies are speciesspecific. For example, human interferon α/β only binds the human interferon α/β receptor and does not directly affect mouse vessels. In addition, antibodies used clinically are often humanized and may not bind mouse antigens. For example, bevacizumab (Avastin; anti-human vascular endothelial growth factor (VEGF)) does not bind mouse VEGF. Therefore, models of human angiogenesis such as the one described in this issue would greatly benefit preclinical drug testing.
A third advantage of the spheroid assay 1 is that the human cells can be genetically manipulated in vitro before injection. A gene of interest could be overexpressed or knocked out (for example, by RNA interference) before implantation, and the effect on various steps in the angiogenesis process could be analyzed. By studying the biology of angiogenesis in this way, one can better understand ways to manipulate or inhibit the process.
An interesting technical point in the new spheroid assay 1 is the choice of matrix, a mixture of Matrigel and fibrin. The major components of Matrigel are laminin and collagen. Fibrin is an insoluble protein formed by the enzymatic action of thrombin on fibrinogen, which normally occurs during blood clot formation and has been implicated in angiogenesis within healing wounds and solid tumors 5 . Fibrin binds heparin with high affinity. Many of the most potent angiogenic growth factors are heparin-dependent in their action 6 . Inclusion of fibrin in the assay obviates the need for exogenous heparin in the system. A noteworthy point is that growth factors VEGF and FGF-2 showed similar angiogenic potencies in vivo using the spheroid
